Clinical Trial Update: BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of BIBF1120 (nintedanib) in advanced urothelial carcinoma, including FGFR3-mutant, FGFR3-overexpressed, or wild-type tumors; statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• BIBF1120 (nintedanib) (nintedanib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Urothelial Carcinoma | Phase 2 | Status: UNKNOWN